GSA Capital Partners LLP Has $979,000 Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

GSA Capital Partners LLP decreased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 95.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 120,169 shares of the company's stock after selling 2,675,319 shares during the period. GSA Capital Partners LLP owned approximately 0.22% of Ginkgo Bioworks worth $979,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Paloma Partners Management Co acquired a new stake in shares of Ginkgo Bioworks in the first quarter valued at about $28,000. Algert Global LLC acquired a new stake in Ginkgo Bioworks during the second quarter worth approximately $36,000. Russell Investments Group Ltd. boosted its stake in Ginkgo Bioworks by 9,440.6% in the 1st quarter. Russell Investments Group Ltd. now owns 31,961 shares of the company's stock valued at $37,000 after purchasing an additional 31,626 shares during the period. Wellington Wealth Strategies LLC. acquired a new position in Ginkgo Bioworks in the 2nd quarter valued at $41,000. Finally, Thoroughbred Financial Services LLC bought a new position in Ginkgo Bioworks during the 2nd quarter worth $70,000. Institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Trading Down 12.9 %

Shares of DNA traded down $0.94 during trading hours on Friday, hitting $6.37. 3,008,390 shares of the company were exchanged, compared to its average volume of 1,149,422. The stock has a market capitalization of $354.01 million, a P/E ratio of -0.49 and a beta of 1.09. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $75.20. The business's fifty day simple moving average is $7.78.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on DNA shares. BTIG Research boosted their target price on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the company a "sell" rating in a research report on Friday, August 23rd. TD Cowen boosted their price objective on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the company a "buy" rating in a report on Friday, September 20th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $4.58.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.